Antigen News and Research

RSS

Atlas Antibodies marks 20 years of Human Protein Atlas–validated antibodies

Atlas Antibodies is 20 years old. The company is the original manufacturer of the antibodies used to map the human proteome in the Human Protein Atlas (HPA).

From Atlas Antibodies AB 30 Sep 2026

Bile DNA sequencing helps identify hidden pancreatobiliary tumors

Distinguishing malignant from benign biliary strictures remains a major clinical challenge. Endoscopic retrograde cholangiopancreatography (ERCP)-guided cytology and biopsy may be inconclusive, particularly in early-stage disease or when tissue is scarce.

29 Sep 2026

Five-treatment radiation provides excellent long-term prostate cancer control

Five-treatment stereotactic body radiation therapy (SBRT) provided excellent long-term cancer control with fewer urinary and sexual side effects than surgery in the first randomized trial to directly compare the treatments for localized prostate cancer.

28 Sep 2026

MIT engineers use artificial intelligence to create heat-resistant RNA vaccines

MIT engineers have found a way to stabilize the lipid nanoparticles used to deliver RNA vaccines, which could allow the vaccines to be more widely distributed.

28 Sep 2026

MD Anderson researchers showcase new findings in radiation oncology at ASTRO 2026

Experts from The University of Texas MD Anderson Cancer Center will present nearly 70 abstracts at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

25 Sep 2026

Review highlights emerging treatments for glioblastoma multiforme

A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled "Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026)."

25 Sep 2026

Laser irradiation boosts antibody-antigen interactions to detect colorectal cancer

Researchers often use antibodies to detect specific molecules or biological markers, as they are remarkably precise at recognizing their targets.

25 Sep 2026

Specialized immune cells bridge the nervous and immune systems

A collaborative team led by Professor Jie Zhou at Tianjin Medical University School of Basic Medicine and Professor Qiang Liu at Tianjin Medical University General Hospital published a comprehensive review in Volume 2 of the journal Immunity & Inflammation on September 8, 2026.

25 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Baseline liver fibrosis severity predicts treatment response in patients with HBeAg-positive CHB

The impact of baseline liver fibrosis severity on the effectiveness of pegylated interferon (Peg-IFN) combined with nucleos(t)ide analogs (NAs) in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) has not been fully clarified.

23 Sep 2026

City of Hope develops adaptive plug-and-play CAR T technology to attack tumors

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, have developed a new "plug-and-play" technology that adds engineered molecules to chimeric antigen receptor (CAR) T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer.

22 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

Adenine base editing slows neurodegeneration in hereditary motor neuron disease

A team of researchers led by Professor Haruhisa Inoue (Center for iPS Cell Research and Application, Kyoto University) and Professor Yuishin Izumi (Tokushima University) demonstrated that adenine base editing can correct a disease-causing genetic mutation and alleviate neurodegeneration in hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P), providing proof of concept for a precision gene therapy for inherited motor neuron diseases.

18 Sep 2026

Scientists reveals how cancer-causing p53 mutations remain invisible to the immune system

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

17 Sep 2026

Celastrol reduces cholestatic liver injury by inhibiting specific protein

Cholestasis occurs when bile formation, secretion, or flow is impaired, causing toxic bile acids to accumulate and trigger inflammation and liver-cell damage.

17 Sep 2026

Innate immune system variations determine vaccine side effects

Redness and pain at the injection site, fever, fatigue or headaches: vaccines can cause side effects, but their frequency and severity vary considerably from person to person.

17 Sep 2026

Specialized imaging technique detects most clinically relevant prostate cancers

An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis.

16 Sep 2026

New AACR report outlines future of cutting-edge cancer research

Today, the American Association for Cancer Research (AACR) released the 16th edition of its annual Cancer Progress Report.

16 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

McMaster researchers discover molecular switch causing dangerous blood clots

A cross-campus team of McMaster University researchers has identified why some patients develop dangerous blood clots after exposure to a common blood thinner – and a potential way to prevent it.

11 Sep 2026